Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis

BACKGROUND: Oral miltefosine has been shown to be non-inferior to first-line, injectable meglumine antimoniate (MA) for the treatment of cutaneous leishmaniasis (CL) in children. Miltefosine may be administered via in-home caregiver Directly Observed Therapy (cDOT), while patients must travel to cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Brandon A., Cossio, Alexandra, Saravia, Nancy Gore, Castro, Maria del Mar, Prada, Sergio, Bartlett, Allison H., Pho, Mai T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404883/
https://www.ncbi.nlm.nih.gov/pubmed/28384261
http://dx.doi.org/10.1371/journal.pntd.0005459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404883/
https://www.ncbi.nlm.nih.gov/pubmed/28384261
http://dx.doi.org/10.1371/journal.pntd.0005459

Ejemplares similares